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There is debate whether interval carcinomas differ from screen-detected tumours biologically. In this study,
clinico-pathological parameters and the expression of well-validated biological markers were compared
between ‘true’ interval carcinomas and screen-detected/missed carcinomas hypothesising that ‘true’ interval
carcinomas show a more aggressive biological behaviour. The study group consisted of 92 consecutive
postmenopausal women attending the breast screening programme and presenting with an invasive ductal
carcinoma. All screening mammograms were re-reviewed. Sixteen patients had a ‘true’ interval carcinoma.
Seven carcinomas were missed at screening, but detected on re-reviewing of the screening mammogram.
Radiological characteristics were assessed from diagnostic mammograms. Data on patient- and tumour
characteristics and follow-up data were recorded from hospital records. Median follow-up was 61 months.
Immunohistochemistry for ER, PR, Her2/neu and p53 was performed on TMA sections. Univariate and
multivariate logistic regression analyses were performed. In univariate analysis, ‘true’ interval carcinomas were
significantly larger (odd ratios (OR) 7.2, 95% CI 1.8–28.1) and less frequently ER (OR 0.3, 95% CI 0.1–0.9) and PR
(OR 0.3, 95% CI 0.1–1.0) positive. In multivariate analysis, ‘true’ interval carcinoma was independently
associated with larger tumours (OR 7.0, 95% CI 1.4–36.2). A trend toward ER negativity was found (OR 0.3, 95%
CI 0.1–1.1). ‘True’ interval carcinomas showed a trend toward a decreased relapse-free survival (HR 1.7 95% CI
0.9–3.1). Although ‘true’ interval carcinomas were significantly larger than screen-detected/missed interval
carcinomas, it remains challenging to observe parameters that determine this difference between ‘true’ interval
carcinomas and screen-detected lesions.
Modern Pathology advance online publication, 15 January 2010; doi:10.1038/modpathol.2009.188
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From 1989 till 1997, a nationwide breast cancer
screening programme has gradually been implemen-
ted in the Netherlands.1 Starting as a biennial
screening mammography for women aged 50–69,
in 1999 the programme was also offered to women
aged 70–75 years. The attendance rate is over 80%
in the northern part of the Netherlands. The
introduction of the screening programme has led to
a substantial decrease in the rate of advanced breast
carcinoma and to a breast cancer mortality decline
of almost 30% in the screened and non-screened
population.2 In spite of the participation in the
screening programme, a number of women still
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present with a clinically symptomatic carcinoma
between two screening moments, a so-called inter-
val carcinoma. In participants in the Dutch Breast
Cancer Screening Programme, 36% of the tumours
emerge as interval carcinomas3 and there is discus-
sion whether interval carcinomas differ from screen-
detected tumours biologically and should therefore
deserve a different, perhaps more aggressive treat-
ment.4 Over the years many studies have been
conducted on the differences between interval-
and screen-detected carcinomas.5–16 Comparison of
these studies is difficult, because of the great
heterogeneity in screening group, screening interval
and study design. Therefore, in this analysis a very
homogeneous group of postmenopausal women is
studied. All women presented with an invasive
ductal carcinoma and participated in the breast
screening programme (as confirmed by the Northern
Netherlands Comprehensive Cancer Centre). The
patients’ screening mammograms were re-reviewed
to differentiate between ‘true’ interval carcinomas
and false-negative mammograms (missed carcino-
mas). We studied the expression of conventional
tumour progression-related biological markers (oes-
trogen receptor (ER), progesterone receptor (PR),
HER2/neu and p53), radiological characteristics
(breast density, tumour outlining and calcifications)
and follow-up data hypothesising that if ‘true’
interval carcinomas are indeed a more aggressive




Screen-detected carcinoma: a carcinoma detected in
the screening programme.
‘Missed’ carcinoma: a clinically detected carcino-
ma that occurred between two screening moments
with a visible lesion on re-reviewing of the screen-
ing mammogram.
Interval carcinoma: a clinically detected carcino-
ma that occurred between two screening moments
after a ‘true’ negative screening mammogram.
Patients
A total of 99 consecutive postmenopausal women
from whom participation in the biannual breast
screening programme could be confirmed by the
Northern Netherlands Comprehensive Cancer Cen-
tre and who were treated between 01 January 1996
and 31 December 2001 at the University Medical
Centre Groningen for a primary operable invasive
ductal carcinoma of the breast as defined by the
WHO classification17 were retrospectively included
in this study. Seven patients were excluded; one
patient because she was already in clinical follow-
up for an earlier in situ lesion and six patients
because their screening mammograms were not
available for re-reviewing. Therefore, the patient
and tumour characteristics and data on follow-up
were obtained retrospectively from hospital records
and are summarised in Table 1. Histology was
reviewed on the original haematoxylin- and eosin-
stained section. The median follow-up was 61
Table 1 Patient and tumour characteristics
n %
Age at diagnosis
Median (range) 60.2 50.2–74.8
Detection
Screen detected 69 75
Interval (‘true’) 16 17.4
Missed 7 7.6













Outlining on screening mammography











Not assessed 1 1.1
Pathological tumour size
o2 cm 52 56.5
42–o5 cm 34 37.0












BCT, breast conserving therapy; cm, centimetre; n, number of cases;
%, percentage.
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months (range 6.3–106.4). Follow-up was performed
according the follow-up guidelines of the Northern
Netherlands Comprehensive Cancer Centre and
consisted of a yearly mammogram in the first 5
years of follow-up and clinical examination (quar-
terly in the first year of follow-up, biannually in the
second year and annually in the third to fifth year.
After 5 years, patients were referred back to the
screening programme.18 During follow-up, four
patients developed a local recurrence after a median
follow-up of 26.7 months. Eleven patients devel-
oped distant metastasis after a median follow-up of
27.3 months. In total, 14 patients presented with a
relapse with a median relapse-free survival of 26.2
months. Five patients died related to breast cancer
with a median overall survival of 28.6 months.
Re-reviewing of Mammograms
The original screening mammogram of all patients
was re-reviewed by two of the investigators (GJdH
and RP), who are both experienced screening
radiologists, to differentiate between ‘true’ interval
carcinomas and interval carcinomas as a result of a
false-negative screening mammogram (missed carci-
nomas). A consensus reading was performed. The
following criteria were used: type 1, nothing to be
observed; type 2, minimal signs only in retrospect;
type 3, significant abnormality. Type 3 tumours were
considered missed carcinomas. There was a max-
imum bias because both radiologists knew the
inclusion criteria and question of the study. Breast
density was scored on clinical mammograms by one
of the investigators (RP) using the Breast Imaging
Reporting and Data Systems (BIRADS) classification
for breast density.19
Tissue Microarray Construction
From the patient’s tumour paraffin block, three
0.6-mm core samples of the most representative
tumour area were included in a tissue microarray.
The technique of tissue microarray production has
been described and validated for breast carcinoma
by others.20,21 In brief, the most representative
tumour area was marked on the original haematox-
ylin- and eosin-stained section. Using this section as
an orientation, three 0.6-mm core punches were
taken from the selected area in the donor blocks and
mounted in a recipient block, using a manual tissue
microarray device (Beecher Instruments, Silver
Springs, MD, USA).
Immunohistochemistry
Immunohistochemistry for ER, PR, Her2/neu and
p53 was performed on sections from the tissue array.
The antibodies and antigen retrieval methods used
are summarized in Table 2. The immunostaining
protocol was as follows: sections were deparafinized
in pure xylene, rehydrated in decreasing concentra-
tions of ethanol and washed in distilled water.
Antigen retrieval was performed. The endogenous
peroxidase reaction was blocked by incubating in
3% perhydrol for 30min. The primary antibody
diluted in PBS containing 1% bovine serum albu-
min (BSA) was incubated for 1 h, after which the
secondary (biotinylated rabbit anti mouse, DAKO,
1:100 diluted in PBS containing 1% BSA and 1%
AB-serum) and tertiary (biotinylated swine anti
rabbit, DAKO, 1:100 diluted in PBS containing 1%
BSA and 1% AB-serum) antibodies were incubated
for 30min each. Visualisation was performed using
the diaminobenzidine tetrahydrochloride/peroxi-
dase reaction. Counterstaining was performed using
haematoxylin. Sections were dehydrated using ris-
ing concentrations of alcohol and were mounted.
Evaluation of Immunohistochemistry
Antibody staining was scored by one investigator
(BvdV), under supervision of an experienced breast
pathologist (JW), who randomly verified the scoring.
ER, PR and p53 were graded based on the percentage
of tumour cells showing positive nuclear staining.
ER and PR were considered positive if nuclear
staining was present in 410% of the cells, and p53
was considered positive in case of a substantial
percentage of positively stained nuclei (430%).
Her-2/neu expression was graded as recommended
by the HercepTest scoring guidelines: 0: no staining
at all or membrane staining in o10% of the tumour
cells; 1þ : a faint/barely perceptible partial mem-
brane staining in 410% of the tumour cells; 2þ :
weak-to-moderate complete membrane staining in
410% of the tumour cells; 3þ : strong complete
membrane staining in 410%. Her-2/neu was con-
sidered to be overexpressed if the score was 3þ .
Table 2 Antibodies and antigen retrieval methods
Antibody Clone Supplier Dilution Antigen retrieval
ER 6F11 Ventana a Tris/HCL 0.1M (pH 9.5) 300 98 1C microwave
PR 1A6 Ventana a Tris/HCL 0.1M (pH 9.5) 300 98 1C microwave
Her2/neu CB11 Ventana a Tris/HCL 0.1M (pH 9.5) 300 98 1C microwave
p53 BP-53-12-1 Biogenix 1:800 Tris/HCL 0.1M (pH 9.5) 300 98 1C microwave
a
Prediluted by supplier.
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Data Analysis
Data analysis was performed using the SPSS 14.0.2
statistical package (SPSS, Chicago, IL, USA). An
univariate logistic regression analysis was per-
formed to assess the odd ratios (OR) of clinico-
pathological variables and biomarkers in ‘true’
interval carcinoma versus screen-detected/missed
carcinoma. All parameters with an OR of 3.0 or
higher in the univariate logistic regression analysis
were then entered into a stepwise multivariate
logistic regression analysis. A Cox regression analy-
sis was performed to assess relapse-free and overall
survival in ‘true’ interval carcinoma versus screen-
detected/missed carcinoma.
Results
Tissue cores from all cases were successfully
included in the TMA. Immunohistochemistry was
assessable in 90 cases (98.0%) for p53, in 88 (96.0%)
for Her2/neu and ER, and in 87 cases (95%) for PR.
The results from the re-reviewing of the mammo-
grams are shown in Table 1. In all, 16 of the 23 cases
marked as interval carcinomas, were retrospectively
‘true’ interval carcinomas. Seven cases showed a
retrospectively visible lesion on the screening
mammogram. A majority of those lesions (5/7) were
now classified as ‘uncertain benign’ in which they
had earlier been classified as ‘benign’. Two cases
were now classified as ‘malignancy suspected’. One
of those cases had originated in very dense breast
tissue, which might have caused the judgement
error. A clinical mammogram was available in 88
cases (96%). Breast density was evenly distributed
between ‘true’ interval carcinomas and screen-
detected/missed carcinomas.
Univariate Analysis
The results of univariate logistic regression analyses
of clinico-pathological parameters and biomarkers
in ‘true’ interval- versus screen-detected/missed
carcinomas are shown in Table 3. A majority of
these parameters did not differ between both groups.
‘True’ interval carcinomas were significantly larger
(OR 7.2, 95% CI 1.8–28.1, P¼ 0.005) and were less
often ER positive (OR 0.3, 95% CI 0.08–0.9,
P¼ 0.034). A trend toward PR negativity (OR 0.3,
95% CI 0.1–1.0, P¼ 0.06) was found in ‘true’
interval carcinomas.
Multivariate Analysis
Table 4 shows the results of a multivariate analysis.
Tumour size was significantly associated with ‘true’
interval carcinoma (HR 5.1, 95% CI 1.2–21.0,
P¼ 0.02). A trend toward ER negativity was also
found (HR 0.3, 95% CI 0.08–1.2, P¼ 0.08). PR was
eliminated from the equation.
Clinical Outcome
The Cox regression analysis showed a trend toward
decreased relapse-free survival in ‘true’ interval
carcinomas (Table 5). No difference in overall
survival was found.
Discussion
This study compared clinical, pathological and radio-
logical variables, the expression of conventional
biomarkers and follow-up data of ‘true’ interval
Table 3 Univariate logistic regression analysis of clinico-patho-
logical variables and biological markers in ‘true’ interval




Age at diagnosis (n¼92) 1.0 (0.9–1.1) 0.808
Mammographic density (BIRADS) (n¼88)
I 1
II 0.5 (0.1–2.6) 0.389
III 0.6 (0.1–2.7) 0.507
IV 1.3 (0.3–5.6) 0.696
Mammographic calcifications (n¼92)
Yes 1
No 1.5 (0.4–5.0) 0.538
Treatment (n¼92)
BCT 1
Mastectomy 1.5 (0.5–4.5) 0.439
Axillary nodal status (n¼91)
Negative 1
Positive 2.4 (0.8–7.2) 0.117
Tumour size (n¼88)
o2 cm 1
42 cm 7.2 (1.8–28.1) 0.005
Grade of differentiation (n¼91)
Well 1
Moderate 0.4 (0.1–1.8) 0.244
Poor 2.0 (0.5–7.4) 0.320
Estrogen receptor (n¼88)
Negative 1
Positive 0.3 (0.1–0.9) 0.034
Progesterone receptor (n¼ 87)
Negative 1
Positive 0.3 (0.1–1.0) 0.06
Her2/neu (n¼ 88)
0/1/2 1
3 1.6 (0.3–8.6) 0.603
P53 (n¼90)
Negative 1
Positive 1.6 (0.2–16.2) 0.701
BCT, breast conserving therapy; cm, centimetre; 95% CI, 95%
confidence interval; HR, hazard ratio; P, significance.
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carcinomas versus screen-detected and missed car-
cinomas, hypothesising that ‘true’ interval carcino-
mas express parameters of aggressive behaviour
more abundantly. ‘True’ interval carcinomas were
larger and showed a trend toward ER negativity and
decreased relapse-free survival.
In Table 6, the results from a literature search on
studies assessing differences between interval- and
screen-detected breast carcinomas conducted in
postmenopausal women are shown. When compar-
ing the results from the studies that defined ‘true’
interval carcinoma with this study, our finding of
increased tumour size and decreased ER expression
in ‘true’ interval carcinoma confirms some of the
results of those studies. Some studies also found
differences in the number of positive axillary lymph
nodes and tumour grade, findings that we could not
confirm. Those findings were never confirmed in
multivariate analysis however.
Several restrictions apply when comparing stu-
dies conducted on the differences between interval-
and screen-detected carcinomas. First, there is large
heterogeneity in study groups, screening interval,
type of breast cancer studied and study design.
Second, most studies, including the current one,
comprise a small study group. One might argue that
these study groups are too small and heterogeneous
to gain sufficient statistical power to observe
differences between screen-detected and interval
carcinomas. To avoid heterogeneity in type of breast
carcinomas and the patient population studied, we
focused on postmenopausal women in the screening
programme, presenting with an invasive ductal
carcinoma as defined by the WHO classification,17
as this is by far the most common type of breast
cancer. Third, most studies use univariate logistic
regression analysis to study differences, making
their findings more susceptible to biases.22 There-
fore, we performed a stepwise multivariate logistic
regression analysis to correct for confounding
factors. Fourth, the definition of an interval carci-
noma differs between studies. Some investigators
define all carcinomas detected clinically between
two screening moments as an interval carcinoma.
This is a correct definition of interval carcinoma
when looking at the sensitivity of the screening
programme as a whole. A portion of those interval
carcinomas, however, are in fact significant lesions
that should have been referred. These tumours are
not detected in the interval between two screening
moments because of their biological behaviour, but
due to restrictions of the screening programme.
Therefore, in this study screening mammograms
were re-reviewed to differentiate between ‘true’
interval carcinomas and interval carcinomas as a
result of a false-negative screening mammogram. We
defined an interval carcinoma as a clinically
detected carcinoma that occurred between two
screening moments after a ‘true’ negative screening
mammogram. Using this definition of interval
carcinoma, the sensitivity of the screening mammo-
gram as a test for detecting breast carcinoma can be
assessed. The programme sensitivity of the Dutch
screening programme was 65% in the nationwide
evaluation of the programme (meaning that for every
two carcinomas discovered in the screening pro-
gramme in the 2 years between screening moments
another carcinoma is discovered clinically). In our
series, the programme sensitivity was 75% (using
the first definition described above). It is plausible
that this difference is caused by the selection of the
study group (only invasive ductal carcinomas were
included). The Dutch National Evaluation Team
Breast Cancer Screening (LETB) has estimated that
in general (ductal carcinoma in situ and lobular
carcinoma included) from all the interval carcino-
mas approximately 50% is a ‘true’ interval carcino-
ma. Approximately 25% of the interval carcinomas
show a clear lesion, for which a patient should have
been referred for additional diagnostics, on re-
reviewing of the screening mammography, and a
further 25% show ‘minimal signs’, that are only
suspicious with the knowledge of a clinically
discovered interval carcinoma. The percentage of
‘true’ interval carcinomas in this series was 30.4%,
which is comparable to those estimations.
‘True’ interval carcinomas were five times more
often larger sized (42 cm) tumours in our series.
Several explanations for the increased size of inter-
val carcinomas have been suggested in literature.
First, interval carcinomas have been associated with
dense breast tissue, with poor outlining and with
absence of calcifications on mammography.12,23,24
Table 4 Independent predictors of ‘true’ interval carcinoma
(n¼ 82)
Parameters OR 95% CI P-value
Tumour size
o2 cm 1
42 cm 5.1 1.2–21.0 0.02
Estrogen receptor
Negative 1
Positive 0.3 0.1–1.2 0.08
cm, centimetre; 95% CI, 95% confidence interval; OR, odds ratio.
Regression analysis by elimination of variables in a stepwise manner.
Table 5 Relapse-free and overall survival for ‘true’ interval
carcinoma versus screen-detected/missed carcinoma
HR 95% CI P-value
Relapse-free survival (n¼ 91)
SD/M carcinoma 1
‘True’ interval carcinoma 1.7 0.9–3.1 0.08
Overall survival (n¼88)
SD/M carcinoma 1
‘True’ interval carcinoma 1.3 0.1–11.6 0.82
95% CI, 95% confidence interval; HR, hazard ratio; SD/M, screen-
detected and missed carcinomas.
Cox regression analysis.
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When tumours from women with dense breasts be-
come clinically apparent after a negative screening
mammogram, they are more ahead in their natural
history compared with screen-detected carcinomas
and are therefore larger, a phenomenon called lead
time bias.25 In our series, breast density was evenly
distributed between screen-detected/missed carcinomas
and ‘true’ interval carcinomas. Second, several
studies suggest that interval carcinomas are rapidly
proliferating tumours. Several different parameters
for proliferation are used in these studies. Two
studies found increased mitotic count and Ki-67
antigen expression in interval carcinomas.7,10 One of
those studies, however, was performed a hetero-
geneous group of breast carcinomas, including
lobular carcinomas, which may have confounded
the results of this study somewhat. Ki-67 immuno-
histochemistry was not performed in this series,
because this expression is very heterogeneous in
ductal breast carcinoma and therefore difficult to
interpret on TMA. Others used fraction of tumour
cells in the S-phase fraction of the cell cycle as a
marker for proliferation and found an increase of
this fraction in interval carcinomas.11,13 In this
Table 6 Significant differences between interval- and screen-detected tumours from literature




































212 98 40–74 2 No Univariate S-phase fraction
Bahnsen et al
(1994)5




267 82 50–64 Varying Yes Univariate Tumour size
Tumour grade

























64 63 40–80 Varying No Univariate Proportion of proliferating
cells
p53 expression
Number of apoptotic cells
Multivariate p53 expression
ki-67 expression
Raja et al (2001)15 625 230 50–64 3 Yes Univariate Tumour grade
Tumour size
Number of positive axillary
lymph nodes
Shen et al (2005)16 712 280 40–64 1 No Multivariate Breast cancer-related death




Adjusted for tumour size.
b
Adjusted for age and tumour size.
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study, we used the Bloom–Richardson scoring
system, of which mitotic count is a part, to assess
grade of differentiation as a marker for prolifera-
tion.26 We did not observe a difference between both
groups of this study. There are other biological
factors outside proliferation rate that may have a
role in the development of breast carcinoma and
may explain the difference in size between ‘true’
interval- and screen-detected/missed carcinoma. For
example, tumour cells from ‘true’ interval carcino-
mas may be less susceptible to apoptosis. One study
assessing the number of apoptotic cells in interval-
and screen-detected carcinomas did not observe a
difference between both groups.10 In addition,
tumours that have a higher angiogenic potential
may grow faster because of reduced tumour cell
death. Another key role player is the amount of
tumour stroma induced that will affect significantly
the size of tumours, especially of invasive ductal
carcinomas, which are known for their highly
variable desmoplasia inducing potential.27 It re-
mains to be established if and to which extent these
explanations contribute to the difference in growth
rate between screen-detected carcinomas/missed
carcinomas and ‘true’ interval carcinomas.
It is assumed that 50–75% of the tumours
discovered in the first screening round are small,
biologically indolent tumours.28–30 These tumours
are more often ER and PR positive. We found that
screen-detected/missed carcinomas were signifi-
cantly more often ER positive in univariate analysis,
a result that is confirmed by other studies.7 This
association only showed a trend toward significance
in multivariate analysis, probably because of the
relatively small sample size of this study. These
relatively less aggressive tumours might also explain
the trend toward increased relapse-free survival we
found for screen-detected carcinomas.
In conclusion, in this small consecutive and
homogeneous study group of postmenopausal wo-
men with invasive ductal breast carcinoma, we
found a significant difference in tumour size
between ‘true’ interval- versus screen-detected/
missed carcinomas in multivariate analysis. ER
expression differed significantly between both
groups in univariate analysis. It remains challen-
ging, however, to observe parameters that determine
this difference between the ‘true’ interval carcino-
mas and screen-detected lesions.
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